本页面由Tiger Trade Technology Pte. Ltd.提供服务

Redhill Biopharma Ltd

0.5150
-0.0184-3.46%
盘后:0.5020-0.0130-2.52%19:49 EDT
成交量:8.21万
成交额:4.21万
市值:313.17万
市盈率:-3.79
高:0.5334
开:0.5145
低:0.5000
收:0.5335
52周最高:2.14
52周最低:0.4351
股本:608.09万
流通股本:608.09万
量比:0.03
换手率:1.35%
股息:- -
股息率:- -
每股收益(TTM):-0.1358
每股收益(LYR):-0.1358
净资产收益率:-1708.61%
总资产收益率:-22.37%
市净率:-2.90
市盈率(LYR):-3.79

数据加载中...

公司资料

公司名字:
Redhill Biopharma Ltd
交易所:
NASDAQ
成立时间:
2009
员工人数:
13
公司地址:
21 Ha’arba’a Street,Tel Aviv-Yafo,Israel
邮编:
6473921
传真:
972 3 541 3144
简介:
Redhill Biopharma Ltd.于2009年8月3日注册成立。该公司是一家专业生物制药公司,主要专注于美国胃肠道疾病、传染病和肿瘤药物的开发和商业化。该公司与Cumberland合作在美国商业化其胃肠道相关产品Talicia,并拥有包括opaganib和RHB-107在内的临床阶段治疗候选药物管线。

董事

名称
职位
Dror Ben Asher
Chairman of the Board and Chief Executive Officer and Director
Kenneth Reed
Independent Director
Ofer Tsimchi
Independent Director
Rick D. Scruggs
Chief Commercial Officer and Director
Roni Mamluk
Independent Director
Shmuel Cabilly
Independent Director

股东

名称
职位
Dror Ben Asher
Chairman of the Board and Chief Executive Officer and Director
Gilead Raday
Chief Operating Officer
Razi Ingber
Chief Financial Officer
Adi Frish
Chief Corporate and Business Development Officer
Guy Goldberg
Chief Business Officer
Rick D. Scruggs
Chief Commercial Officer and Director